AstraZeneca to receive up to $400 million to co-develop Parkinson’s drug

News

Author: Parkinson's Life editorsPublished: 31 August 2017

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

AstraZeneca and Takeda lead

AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after agreeing a deal to co-develop an early-stage medicine for Parkinson’s disease.

The drug, MEDI1341, is an antibody treatment and is due to enter phase I clinical trials later this year.

Mene Pangalos, executive vice president of AstraZeneca, said: “By combining our scientific expertise and sharing the risks and cost of development, we hope to accelerate the advancement of MEDI1341 as a promising new approach to support the treatment of people with Parkinson’s disease around the world.”

The two companies will share future development and commercialisation costs for MEDI1341 equally, in addition to future revenues.

Go Back

Share this story

Comments


Related articles


Parkinson's hospitals

Special reports

Are UK hospitals safe for people with Parkinson’s?

Two thirds of Parkinson’s patients do not get their medication on time

READ MORE
Russell Patten EPDA secretary general

Europe

Meet the EPDA’s new secretary general

On World Parkinson's Day we talk to Russell Patten

READ MORE
Tony Seidl lead

Europe

Tony’s two-wheel tour: a man, a bike and a Parkinson’s promise

Daily diary entries during epic 11-day bike tour across the Alps

READ MORE